Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Share this article:
Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Sponsor and Collaborators

Assistance Publique - Hôpitaux de Paris

Contact
Contact: Zakia Idir, PhD
+33 1 4484 1747
zakia.idir@sls.aphp.fr

Principal Investigator
Celeste Lebbe, MD, PhD Hôpital Saint-Louis, Paris, France

ClinicalTrials.gov Identifier
NCT01168050
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Melanoma Clinical Trials

Clinical Trial: Study of Tumor Tissue Samples From Patients With Stage I, ...

Clinical trial focusing on tumor tissue samples and malignant melanoma. Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Clinical Trial: Evaluating the Safety and the Biological Effects of Intratumoral Interferon ...

Clinical trial focusing on intraturmoral interferon gamma and peptide based vaccine. Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (Mel 51)

Clinical Trial: Study of Families With Melanoma

Clinical trial focusing on families with melanoma. Study of Families With Melanoma